Imatinib induces senescence in K562 leukemic cells marked by growth arrest, p21Cip1, p27 induction, and enhancement of SA-β-gal activity, while nilotinib induces senescence in H1975 NSCLC cells marked by increased SA-β-gal activity [100,101]. The gene discussed is CDKN1A; the disease is non-small cell lung carcinoma.